News
Zacks Investment Research on MSN14d
MIST Stock Falls 66% Following Complete Response Letter for CardamystMilestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback